Artificial Intelligence in Mass Spectrometry-Based Metabolomics and Lipidomics for Drug Discovery and Development.

Authors

Young Cheol Yoon, Seoyeon Choi, Cheol Woon Jung, Hendra Mahakam Putra, Young Jin Min, Sun Jo Kim, Sung Won Kwon

Published in

Biomolecules & therapeutics. Oct 08, 2026. Epub Oct 08, 2026.

Abstract

Artificial intelligence applied to mass spectrometry-based metabolomics and lipidomics has advanced through three technological generations: chemometric and classical machine learning, deep learning, and self-supervised foundation models, with large language models so far entering mainly at the edges. The metabolome and lipidome lie closest to drug action, yet they have been among the slowest omics layers to adopt modern artificial intelligence. This paradox arises from their downstream position, which leaves them without a closed molecular reference and without the standardized, readily modeled data available to the genome and transcriptome. This review examines what these methods contribute to drug discovery and development. We survey applications across the drug-development pipeline, from target identification and mechanism-of-action deconvolution, through the prediction of drug-induced toxicity, to pharmacometabolomics, in which pre-dose metabolic phenotypes inform patient stratification and dosing. Across these metabolomic and lipidomic applications, interpretable classical machine learning remains the dominant form of artificial intelligence. The newer deep-learning and foundation models have concentrated instead on compound annotation, the cross-cutting problem of assigning confident identities to spectra, yet successive generations have mitigated but not solved it. Beyond annotation confidence, batch effects, semi-quantification, and small-cohort overfitting also remain practical constraints. Overall, targeted, hypothesis-driven metabolomic and lipidomic studies can already support drug discovery when their inferences are restricted to confidently identified metabolites, whereas open, hypothesis-free discovery remains the frontier. Near-term progress will depend less on any single algorithm than on curated spectral resources, rigorous measurement, leakage-aware validation, and honest reporting of identification confidence.

PMID:
42844781
Bibliographic data and abstract were imported from PubMed on 08 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.